New tools improve care for cancers that spread to the brain

October 05, 2020

Ambitious efforts at UVA Cancer Center to improve care delivered to patients with cancer that has spread to the brain have yielded important insights and tools that can benefit other hospitals, a new publication reports.

The tools include the first set of metrics to assess care provided for these secondary tumors, known as brain metastasis. The UVA team says its findings will help doctors and patients make better-informed treatment decisions, enhance the care of brain metastases, and enable hospitals to improve the coordination and effectiveness of their interdisciplinary treatment programs.

"The proposed set of measurements serves as the framework to gauge the performance of multidisciplinary programs, with the goal of providing optimal consistent and coordinated care to patients with brain metastasis," said Camilo E. Fadul, MD, a neuro-oncologist at UVA Health and UVA Cancer Center.

Quality Care for Brain Metastases

Brain metastases are the most common tumors affecting the central nervous system. Although any type of cancer can spread to the brain, the most frequent are lung cancer, breast cancer and melanoma.

As patients with cancer are living longer, the frequency of brain metastasis is on the rise. So doctors are seeking to personalize treatment from a menu of options that include surgery, radiation (either targeted stereotactic radiosurgery or whole brain radiation), chemotherapy, targeted oral therapies and immunotherapy. Because of the complexity of treatment decisions and the need to provide safe and consistent patient-centered care, UVA takes an interdisciplinary approach, which brings together providers with expertise in radiation oncology, neuro-oncology, medical oncology, neurosurgery and palliative care.

While developing this program, the UVA group led by Dr. Fadul identified relevant outcome measurements to inform treatment decisions, evaluate the care process and implement interventions that will improve value. They tested the measurements by looking at hundreds of patients' data to identify strategies that will improve outcomes, and they reviewed every detail of UVA's care for patients, beginning with their brain metastasis diagnosis and ending with the patients' discharge.

They identified relevant outcome measurements for patients receiving brain metastases directed treatment by looking at survival - specifically, survival more than 90 days after the important milestones of diagnosis, surgery, stereotactic radiosurgery and whole-brain radiation therapy. Other measurements examined processes that may translate in better outcomes, such as whether patients had advance directives outlining the type of care they wish to receive documented in their electronic medical record, if they had palliative care consultation and if the drug memantine, which may protect cognitive function from possible radiation injury, was prescribed to patients receiving whole-brain radiation therapy.

"The proposed set of performance measurements serves as the foundation for improving healthcare delivery, for characterizing the structure, processes and functions of the optimal interdisciplinary teams, and for filling the gap associated with disparities in the quality of the care and outcomes after diagnosis of brain metastases," Dr. Fadul said.

He noted the measurements need to incorporate the input and perspective from patients and caregivers -- what are called "patient-reported outcomes." In addition, the metrics have to be refined and validated by other experts in the field. Several projects are already underway to build upon these results and further improve the care provided to patients with brain metastasis at UVA.

"Identification of areas for quality improvement, sharing among hospitals of data and strategies that improve outcomes, and development of consistent treatment guidelines based on continuous performance measurements, like the ones we proposed, will enhance the quality and value of the care provided to the growing population of patients afflicted with brain metastasis," Dr. Fadul said.
-end-
Findings Published

The findings have been published in the scientific journal JCO Oncology Practice. The group contributing to this work consisted of Julio Silvestre, Tracey Gosse, Paul Read, Ryan Gentzler, Benjamin Purow, Ashok Asthagiri, Elizabeth Gaughan, Patrick M. Dillon, James M. Larner, Roger T. Anderson, Jason P. Sheehan and Camilo E. Fadul. A full list of the authors' disclosures is included in the paper.

To keep up with the latest medical research news from UVA, subscribe to the Making of Medicine blog at http://makingofmedicine.virginia.edu.

University of Virginia Health System

Related Breast Cancer Articles from Brightsurf:

Oncotarget: IGF2 expression in breast cancer tumors and in breast cancer cells
The Oncotarget authors propose that methylation of DVDMR represents a novel epigenetic biomarker that determines the levels of IGF2 protein expression in breast cancer.

Breast cancer: AI predicts which pre-malignant breast lesions will progress to advanced cancer
New research at Case Western Reserve University in Cleveland, Ohio, could help better determine which patients diagnosed with the pre-malignant breast cancer commonly as stage 0 are likely to progress to invasive breast cancer and therefore might benefit from additional therapy over and above surgery alone.

Partial breast irradiation effective treatment option for low-risk breast cancer
Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast irradiation for many women with low-risk, early stage breast cancer, according to new clinical data from a national clinical trial involving researchers from The Ohio State University Comprehensive Cancer Center - Arthur G.

Breast screening linked to 60 per cent lower risk of breast cancer death in first 10 years
Women who take part in breast screening have a significantly greater benefit from treatments than those who are not screened, according to a study of more than 50,000 women.

More clues revealed in link between normal breast changes and invasive breast cancer
A research team, led by investigators from Georgetown Lombardi Comprehensive Cancer Center, details how a natural and dramatic process -- changes in mammary glands to accommodate breastfeeding -- uses a molecular process believed to contribute to survival of pre-malignant breast cells.

Breast tissue tumor suppressor PTEN: A potential Achilles heel for breast cancer cells
A highly collaborative team of researchers at the Medical University of South Carolina and Ohio State University report in Nature Communications that they have identified a novel pathway for connective tissue PTEN in breast cancer cell response to radiotherapy.

Computers equal radiologists in assessing breast density and associated breast cancer risk
Automated breast-density evaluation was just as accurate in predicting women's risk of breast cancer, found and not found by mammography, as subjective evaluation done by radiologists, in a study led by researchers at UC San Francisco and Mayo Clinic.

Blood test can effectively rule out breast cancer, regardless of breast density
A new study published in PLOS ONE demonstrates that Videssa® Breast, a multi-protein biomarker blood test for breast cancer, is unaffected by breast density and can reliably rule out breast cancer in women with both dense and non-dense breast tissue.

Study shows influence of surgeons on likelihood of removal of healthy breast after breast cancer dia
Attending surgeons can have a strong influence on whether a patient undergoes contralateral prophylactic mastectomy after a diagnosis of breast cancer, according to a study published by JAMA Surgery.

Young breast cancer patients undergoing breast conserving surgery see improved prognosis
A new analysis indicates that breast cancer prognoses have improved over time in young women treated with breast conserving surgery.

Read More: Breast Cancer News and Breast Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.